Showing results (371-380 of 436) with videos related to
Sort By:
Pageof 44
Blood|August 16, 2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaSagar Lonial, Edmund K Waller, Paul G Richardson, et al.Leukemia Research|October 17, 2013
The clinical significance of cereblon expression in multiple myelomaSteven R Schuster, K Martin Kortuem, Yuan Xiao Zhu, et al.Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.Journal of Immunological Methods|October 2, 2021
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samplesSasha E Larsen, Bryan J Berube, Tiffany Pecor, et al.British Journal of Haematology|July 23, 2009
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Lee Wolf, et al.Leukemia|August 8, 2021
Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroupsEileen M Boyle, Adam Rosenthal, Hussein Ghamlouch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)Valerie W Rusch, Dorothy J Giroux, Michael J Kraut, et al.Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.Blood|January 28, 2009
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose, Thierry Rème, Tobias Meissner, et al.Biotechnology and Bioengineering|March 12, 2020
Beyond heuristics: CFD-based novel multiparameter scale-up for geometrically disparate bioreactors demonstrated at industrial 2kL-10kL scalesJames Scully, Laura B Considine, Mark T Smith, et al.Pageof 44